Fair Money & Economic Opportunity

Alzamend Neuro, Inc. is a preclinical stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases and psychiatric disorders.

Its core business does not involve lending, insuring, moving, or storing money for consumers. Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility for financial data, fair lending compliance, wealth building outcomes, financial literacy initiatives, debt burden ratio, geographic inclusion for banking services, and product simplicity for financial products, are not applicable to the company's operations. The company intends to retain any future earnings to support operations and finance business growth, which aligns with standard profit retention policies rather than community finance reinvestment.

Fair Pay & Worker Respect

For the fiscal year ending 2024, the CEO-to-median employee pay ratio was 3:1.

The CEO's total compensation was $443,617, and the median employee pay was $130,000.

Honest & Fair Business

The company has a formal whistleblower protection policy that outlines procedures for reporting concerns regarding accounting, internal controls, or auditing matters, including options for anonymous reporting and an explicit prohibition against retaliation.

However, there is no evidence of independent investigation processes. The board of directors has outlined criteria for director independence, and 75% of its members are identified as independent. The company's independent auditor's role is detailed, including pre-approval of audit and non-audit services, indicating some level of third-party verification for financial reporting.

Planet-Friendly Business

The provided articles focus exclusively on the company's financial performance, clinical trial updates, and regulatory compliance related to Nasdaq listing requirements.

There is no information or data available in these articles regarding any environmental metrics, initiatives, or policies relevant to the 'Planet-Friendly Business' value, such as carbon emissions, renewable energy use, waste management, water consumption, or climate-related disclosures.

Respect for Cultures & Communities

The provided articles, which include a whistleblower policy, corporate governance documents, and information on clinical trial initiations, do not contain any specific, concrete data points relevant to the 'Respect for Cultures & Communities' value.

Consequently, no evidence was found for formal partnerships with community groups, reinvestment in local development, cultural appropriation incidents, cultural impact assessments, local employment ratios, community grievance mechanisms, cultural preservation investments, local procurement, indigenous suppliers, cultural site protection, social license to operate, charitable giving to cultural organizations, community fund allocations, language inclusivity, cultural incident response, or cultural sensitivity training.

Safe & Smart Tech

The company's privacy policy states it collects only necessary data

and has data retention schedules , which aligns with standard data collection and retention practices. It also mentions user rights to request data correction, update, amendment, or removal , and provides data access and deletion capabilities , reflecting industry-standard user data controls. The policy explicitly states CCPA compliance and outlines data subject rights , indicating basic compliance with applicable regulations.

Zero Waste & Sustainable Products

No information regarding Alzamend Neuro, Inc.'s waste management practices, product sustainability, or related metrics is available in the provided articles.

The articles focus on short borrow rates and SEC filing types, neither of which contains data relevant to the 'Zero Waste & Sustainable Products' ethical value.